Ultime notizie per SIGNA Sports United (OTC:SSUNF) Azioni

SIGNA Sports United NV is a group of specialist sports webshops powered by its sports commerce and technology platform. The company's segment includes Tennis; Bike and Outdoor and Teamsport. It generates maximum revenue from the Bike and Outdoor segment. Geographically, it derives a majority of revenue from Germany.

SIGNA SPORTS UNITED N.V. by SIGNA Sports United N.V.

SIGNA Sports United NV

Baird analyst Andrew Wittmann maintains AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) with a Outperform and raises the price target from $108 to $118.

News

Price Target

Analyst Ratings

Baird Maintains Outperform on AECOM, Raises Price Target to $118

<ul>
<li>Breast surgeons expressed strong interest in participating in&nbsp;IceCure's planned post-market study for ProSense&#xAE; in the treatment of early-stage breast cancer</li>
<li>ICE3 study named as one of the "Best Papers of 2024"&nbsp;</li>
<li>Cryoablation was mentioned favorably during the ASBrS Presidential Address</li>
</ul>
&nbsp;<a href="https://icecure-medical.com/">IceCure Medical Ltd.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCM#NASDAQ">ICCM</a>) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it participated in the American Society of Breast Surgeons (ASBrS) 2025 Annual Meeting on April 30 – May 4, 2025 in Las Vegas.
"We couldn't be more pleased with the high level of interest in ProSense&#xAE; at the ASBrS 2025 Annual Meeting and the reaction of breast surgeons to the recent positive U.S. Food and Drug Administration ("FDA") development regarding our cryoablation system's pathway to marketing authorization," stated Eyal Shamir, IceCure's Chief Executive Officer. "A large number of doctors approached our booth, asking how they could participate in our planned post-market study and how they could offer ProSense&#xAE; to their patients following marketing authorization. We were fortunate that cryoablation for breast cancer was included in prominent presentations by thought leaders, including in the Presidential Address and the Best Papers of 2024 review, putting a spotlight on our technology which we believe can offer greater choice to women with early-stage breast cancer."&nbsp;&nbsp;&nbsp;
The Company's participation included:
<ul>
<li>Exhibiting its&nbsp;ProSense&#xAE; cryoablation system at its booth and providing hands-on demonstrations; &nbsp;</li>
<li>Sponsoring and participating in the pre-conference ultrasound course where hands-on&nbsp;ProSense&#xAE; training was provided; and</li>
<li>Hosting an Expert Booth meeting titled "The Future of&nbsp;Cryoablation in Breast Cancer: A Focus on the Patient Journey" with featured speaker Dr. Nathalie Johnson, former ASBrS President, and guest speaker Dr. Richard Fine, ICE3 Investigator</li>
</ul>
During the ASBrS Presidential Address, cryoablation was positively mentioned and the importance of breast surgeons needing to have the skills to provide all therapeutic procedures for their patients was underscored—including minimally invasive and percutaneous procedures, such as cryoablation. The address specifically mentioned the ICE3 study and stated that the ASBrS awaits a final decision from the FDA for breast cancer cryoablation.
Additionally, the ICE3 study was included in the Best Papers of 2024 review where a summary of the data was presented, and it was noted that cryoablation is a technique that should be "in the hands of" breast surgeons.
On April 30, 2025, IceCure announced it concluded a meeting with the FDA's&nbsp;Center for Devices and Radiological Health regarding the Company's De Novo marketing authorization request for ProSense&#xAE; in the treatment of early-stage low risk breast cancer when combined with adjuvant endocrine therapy for women aged 70 and over. During the meeting, the FDA requested that IceCure conduct a study after marketing authorization has been granted, with the aim of producing additional data in this indication. IceCure will present its post-market study plan, which is expected to include a minimum of 400 patients at 25 sites, to the FDA, and upon the approval of such plan, the FDA's final marketing authorization decision is expected.

Biotech

General

ICCM

Icecure Medical Announces It Participated In the American Society Of Breast Surgeons 2025 Annual Meeting On April 30 – May 4, 2025 In Las Vegas Following Recent FDA Development On ProSense Cryoablation

WIIM

NCNA

NuCana shares are trading lower after the company announced a registered direct offering with approximately $7 million gross proceeds.

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/05/05/final-trades-rockwell-automation-alerian-mlp-lockheed-martin-and-stryker.html">Halftime Report Final Trades</a>,&#8221; Brian Belski, chief investment strategist at BMO Capital Markets, named Rockwell Automation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) as <a href="https://www.benzinga.com/quote/ROK/earnings">his final trade</a>.
On the earnings front, Rockwell Automation will report its second quarter fiscal 2025 results on Wednesday, May 7, before the opening bell. Analysts expect the company to report quarterly earnings at $2.12 per share, down from $2.5 per share in the year-ago period. Rockwell Automation projects quarterly revenue of $1.97 billion for the quarter, compared to $2.13 billion a year earlier.
Anastasia Amoroso, chief investment strategist at iCapital, picked Alerian MLP ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMLP#NYSE">AMLP</a>) as her final trade.
Alerian MLP, on Feb. 11, declared a first-quarter distribution of $0.97.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Jim Lebenthal of Cerity Partners named Lockheed Martin Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>).
Supporting his view, Lockheed Martin posted better-than-expected results for the first quarter on April 22. The company reported a  4% year-over-year increase in net sales to $18.0 billion, beating the consensus of $17.8 billion. It clocked a GAAP EPS of $7.28, beating the consensus of $6.32.
Joseph M. Terranova, senior managing director for Virtus Investment Partners, picked Stryker Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) as his final trade.
Lending support to his choice, Stryker reported quarterly earnings of $2.84 per share on May 1, beating the analyst consensus estimate of $2.70 per share. The company also reported quarterly sales of $5.87 billion, beating the analyst consensus estimate of $5.70 billion.
Price Action:
<ul>
<li>Rockwell Automation shares climbed 0.1% to close at $253.84 on Monday.</li>
<li>Alerian MLP ETF fell 1.9% during Monday's session.</li>
<li>Lockheed Martin shares slipped 0.3% to close at $471.56 on Monday.</li>
<li>Stryker shares rose 0.8% to settle at $381.36.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45193793/top-3-tech-and-telecom-stocks-that-may-jump-this-quarter">Top 3 Tech And Telecom Stocks That May Jump This Quarter</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Markets

Media

Trading Ideas

AMLP

Stryker, Lockheed Martin, Rockwell Automation And More On CNBC's 'Final Trades'

Offerings

ZCAR

Zoomcar Holdings Files Prospectus For Public Offering Of 3.7M  Shares Of Common Stock

Baird analyst Jeff Johnson maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Outperform and lowers the price target from $130 to $115.

Baird Maintains Outperform on Zimmer Biomet Holdings, Lowers Price Target to $115

Sabre's multi-source content platform now features Air France and KLM's NDC offers, giving travel agencies access to exclusive fares, continuous pricing, and richer travel options
SOUTHLAKE, Texas, May 6, 2025 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4420392-1&amp;h=3642424898&amp;u=https%3A%2F%2Fwww.sabre.com%2F&amp;a=Sabre+Corporation">Sabre Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABR#NASDAQ">SABR</a>), a leading global travel technology company, today activated Air France's and KLM's New Distribution Capability (NDC) content in its travel marketplace. Sabre-connected agencies can now access extra options, exclusive promotions, and better fares thanks to continuous pricing, for both of Air France and KLM, helping them stay competitive in an evolving travel retail landscape.
NDC is a critical enabler of modern retailing, allowing airlines to create and distribute personalized offers beyond traditional static fare structures. Through this collaboration with Sabre, Air France and KLM can provide richer content and more competitive price points in the indirect channel, while Sabre-connected travel agencies benefit from seamless access to this content via Sabre's Offer and Order APIs, Sabre Red 360, Sabre Red Launchpad,&#x2122; as well as a range of online booking tools.

Global

SABR

Sabre Activates Air France's And KLM's New Distribution Capability Content In Its Travel Marketplace

FOXO

FOXO Technologies shares are trading higher after the company announced that its Myrtle recovery centers subsidiary has seen over 400 patients since August 2023.

Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMD#NASDAQ">VMD</a>), an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, announced that it has entered into a definitive agreement to acquire Illinois-based Lehan's Medical Equipment ("Lehan"), a healthcare company offering home medical equipment with specialties in respiratory care and women's health.
In 2024, Lehan generated net revenues of approximately $25.7 million and Adjusted EBITDA of approximately $7.4 million. See "Non-GAAP Financial Measures" for a discussion of Adjusted EBITDA. The transaction is expected to close in the third quarter of 2025 for a base purchase price of $26 million, subject to customary net working capital adjustments and an estimated $2.2 million of contingent payments. Viemed expects to fund the acquisition through a combination of cash on hand and borrowings from its existing credit facilities.
 &nbsp;

Viemed Healthcare Agrees To Acquire Lehan's Medical Equipment For Base Purchase Price Of $26M

NuCana plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>), a clinical-stage biopharmaceutical company that focuses on significantly improving treatment outcomes for patients with cancer, announced that it has priced a registered direct offering consisting of 10,845,985 American Depository Shares, or ADSs, (or pre-funded warrants in lieu thereof) with each ADS (or pre-funded warrant) accompanied by (i) a Series A warrant to purchase one (1) ADS at an initial exercise price of $0.8068 per share and (ii) a Series B Warrant to purchase one (1) ADS at an initial exercise price of $1.61 per share. The combined public offering price of each ADS together with the accompanying Series A and Series B Warrants is $0.6454, and the combined offering price of each pre-funded warrant together with the accompanying Series A and Series B warrants is $0.6454, minus the United States dollar equivalent of £0.01, based on the exchange rate on the date of pricing. The gross proceeds of the offering are expected to be approximately $7 million before deducting placement agent fees and offering expenses and are expected to be used to fund activities relating to the advancement of our drug discovery and development programs, and for other general corporate purposes, including, but not limited to, working capital, capital expenditures, investments, acquisitions, should we choose to pursue any, and collaborations. The closing of the offering is expected to occur on or about May 7, 2025, subject to the satisfaction of customary closing conditions.

NuCana Prices Registered Direct Offering For Gross Proceeds Of ~$7M

<a href="https://www.globenewswire.com/Tracker?data=odgTyN9-hUPPWq48DiWe1IWEYS4ZOfxhoUajsmDMfczMmj7epWQ5i6jm4uB2NNb3p0nZdk-M6SnOD-iJH5CljoWeqExAo-FHlOx5s0Thgmc=">Banzai International, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNZI#NASDAQ">BNZI</a>) ("Banzai" or the "Company"), a leading marketing technology company that provides essential marketing and sales solutions, today announced it has expanded its agreement with RBC Capital Markets.
As part of the expanded agreement, RBC&nbsp;Capital Markets' Wealth Marketing Division will have an enterprise license for usage of OpenReel, Banzai's leading digital video creation platform.
"This agreement reinforces our strategy of expansion in the&nbsp;enterprise," said Joe Davy, Founder and CEO of Banzai. "Having already been working with RBC Global Asset&nbsp;Management, this deal shows movement throughout the enterprise into the wealth marketing&nbsp;division, doubling our current engagement&nbsp;and validating our growth&nbsp;in the enterprise space. We are seeing solid traction in the financial sector, where the&nbsp;OpenReel Creator tool gives global financial firms the ability to offer standardized branded video with personalization at scale for their wealth managers, partners, and other stakeholders."
OpenReel empowers organizations to efficiently produce high-quality, branded video content at scale. Its platform enables users to remotely direct, record, edit, and collaborate on professional-grade video projects, significantly streamlining the production process and ensuring brand consistency. OpenReel serves a global enterprise client base, including industry leaders like Bristol Myers Squibb, Ingram Micro, DXC Technology, Insider Inc., and US Steel.
About RBC Capital Markets
The most significant corporations, institutional investors, asset managers, private equity firms, and governments around the globe recognize RBC Capital Markets as an innovative, trusted partner with an in-depth expertise in capital markets, banking, and finance. We are well-established in the largest, most mature capital markets across North America, Europe, and the Asia Pacific region, which collectively encompasses 80% of the global investment banking fee pool.

Contracts

BNZI

Banzai Enters Expanded Agreement With RBC Capital Markets For OpenReel Enterprise License

<ul>
<li>All dosed patients have passed one-year milestone required by U.S. Food and Drug Administration (FDA) for Accelerated Approval regulatory pathway for ST-920.</li>
<li>According to preliminary analysis, mean estimated glomerular filtration rate (eGFR) slope at 52-weeks continued to remain positive.</li>
<li>Productive Type B Chemistry, Manufacturing and Controls (CMC) meeting with FDA provided clear CMC pathway to planned Biologics License Application (BLA) submission.</li>
<li>Pivotal data readout expected by end of second quarter of 2025.</li>
</ul>

SGMO

Sangamo Therapeutics Announces Derisking Milestones For Pathway To Anticipated BLA Submission For ST-920 In Fabry Disease

Baird analyst Catherine Ramsey maintains Twist Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) with a Outperform and lowers the price target from $54 to $44.

TWST

Baird Maintains Outperform on Twist Bioscience, Lowers Price Target to $44

MFA Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MFA#NYSE">MFA</a>) reported quarterly earnings of $0.29 per share which missed the analyst consensus estimate of $0.32 by 9.38 percent. This is a 17.14 percent decrease over earnings of $0.35 per share from the same period last year. The company reported quarterly sales of $57.54 million which beat the analyst consensus estimate of $50.50 million by 13.93 percent. This is a 20.34 percent increase over sales of $47.81 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

MFA Finl Q1 Adj. EPS $0.29 Misses $0.32 Estimate, Sales $57.54M Beat $50.50M Estimate

XPEL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPEL#NASDAQ">XPEL</a>) sees Q2 sales of $117.000 million-$119.000 million vs $118.80 million analyst estimate.

Guidance

XPEL

XPEL Sees Q2 Sales $117.000M-$119.000M vs $118.80M Est

Two posters presented at Digestive Disease Week (DDW) 2025
Preclinical results indicate that PALI-2108 effectively modulates inflammatory pathways in the colon, promoting a favorable immune response
Company advancing Phase 1a/b study of PALI-2108 and has demonstrated a favorable safety profile in single-ascending-dose cohorts
Carlsbad, CA, May 06, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the presentation of positive preclinical data from PALI-2108, an orally administered, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients with ulcerative colitis (UC). The presented data highlighted the efficacy and safety profile of PALI-2108 in a mouse model of colitis, with a particular focus on its impact on PDE4B expression, cAMP levels, and TNF-α suppression as well as predicting efficacious PALI-0008 levels in patients.
The first poster titled, "PALI-2108, A Colon-Specific PDE4 Inhibitor Prodrug, as Bioactivated in the Colon and Reduces Colon Tissue PDE4B in a Dose-Dependent Manner, Increasing c-AMP and Suppressing TNF-α in A Mouse Model of Colitis" was presented as a Poster of Distinction as part of the "In Vivo Models of Gastrointestinal Disorders"&nbsp;session at Digestive Disease Week&#xAE; (DDW) 2025 being held May 3–6, in San Diego, California.

PALI

Palisade Bio Presents Preclinical Data Highlighting Potential Of PALI-2108 As A Colon-Specific PDE4 Inhibitor For The Treatment Of Ulcerative Colitis And Other Inflammatory Bowel Diseases

Patent Expands Protection of TAMP therapy platform, Including Methods to Deliver an Agent, such as a Chemotherapeutic Drug, Near a Tumor
RenovoRx Currently Holds a Strong and Growing IP Portfolio with 19 Issued Patents and 12 Pending Patents Supporting the Commercialization of RenovoCath Device
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Furl.avanan.click%2Fv2%2F___https%3A%2Frenovorx.com%2F___.YXAzOnNoYXlnbGVubmxscDphOm86NDg1N2VmMDZhOWU3YzNhNTY5YTk1MTAxY2M0ODI0ODQ6Njo4MTJmOmQ0MzAxZmM5NTY5ODA4ZWI3MGYwNGI1YTQ5YTE4MTRiYWQ5NDEzNDQxNzRlODllZjJlMjMwNDUxODQzYzljZmQ6cDpUOk4&amp;esheet=54249590&amp;newsitemid=20250506838726&amp;lan=en-US&amp;anchor=RenovoRx%2C+Inc&amp;index=1&amp;md5=c76e401afe2f1716814686eb10b5163f">RenovoRx, Inc</a>. ("RenovoRx" or the "Company") (NASDAQ:<a href="https://www.benzinga.com/stock/RNXT#NASDAQ">RNXT</a>), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath&#xAE;, a novel, FDA-cleared drug-delivery device, today announced that it has received an Issue Notification from the U.S. Patent and Trademark Office (USPTO) indicating that U.S. patent NO. 12,290,564, becomes effective today, May 6, 2025.

RNXT

RenovoRx Secures New U.S. Patent For RenovoRx, Novel Trans-Arterial Micro-Profusion Therapy Platform

XPEL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPEL#NASDAQ">XPEL</a>) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $0.27 by 14.81 percent. This is a 6.9 percent increase over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $103.81 million which beat the analyst consensus estimate of $97.40 million by 6.58 percent. This is a 15.21 percent increase over sales of $90.10 million the same period last year.

XPEL Q1 EPS $0.31 Beats $0.27 Estimate, Sales $103.81M Beat $97.40M Estimate

Baird analyst Mike Polark maintains Inspire Medical Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSP#NYSE">INSP</a>) with a Outperform and raises the price target from $230 to $236.

Comments

SIGNA Sports United

Notizie

Ultime notizie per SIGNA Sports United (OTC:SSUNF) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO